Evidence map›Paper›PMID 40379793›Full record

ArticleScientific reports2025

Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk.

Minjia Xie, Seth S Martin, Alexander Turchin

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Minjia XieNortheastern University School of Pharmacy, Boston, MA, USA.
Seth S MartinJohns Hopkins Medicine, Baltimore, MD, USA.
Alexander TurchinDivision of Endocrinology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA, 02115, USA. aturchin@bwh.harvard.edu.

Funding

Patient-Centered Outcomes Research Institute ME-2019C1-15328
6 · The paper itself

Abstract

Statins are a cornerstone of cardiovascular risk reduction. Nevertheless, non-acceptance of statin therapy recommendations by patients at high cardiovascular risk is common. The reasons for statin non-acceptance have not been well established. We conducted a manual record review of a randomly selected set of patients who did not accept statin therapy recommendations to identify (a) documented reasons for statin non-acceptance and (b) patients' demographic characteristics, comorbidities and current treatment. We analyzed the relationships between patients' characteristics and reasons for statin non-acceptance. The most common reasons for statin non-acceptance were preference for lifestyle modifications (51.5%), general aversion to medications (19.1%), polypharmacy burden (17.1%) and fear of adverse reactions (10.9%). Patients taking more medications were more likely to express a concern about polypharmacy burden (OR 1.09; 95% CI 1.005-1.18). Patients who previously had adverse reactions to non-cholesterol lowering medications were more likely to fear adverse reactions to statins (OR 1.13; 95% CI 1.001-1.28). Patients who expressed preference for lifestyle modifications had time to low density lipoprotein cholesterol (LDL-C) < 100 mg/dL similar to patients who did not accept statin therapy for other reasons (1935 vs. 1777 days, p = 0.26). Patients' reasons for non-acceptance of statin therapy are often linked to their past and present medical experience. Appropriately addressing these concerns is important to maximizing cardiovascular risk reduction in individuals who may be reluctant to initiate statin therapy.

Indexed as

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsAgedFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPolypharmacyHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID40379793
PMCPMC12084616

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.